Amgen Inc Stock Forecast for 2023 - 2025 - 2030
Updated on 06/03/2023
Amgen Inc Stock Forecast and Price Target
Amgen Inc's most recent price target of $278.00 for 2023 was provided by eleven renowned analysts over the past few months, with an average prediction of $278.00. If this prediction is correct, Amgen Inc's stock could rise by 27.48 percent from its current trading price. The potential increase for the stock is $278.00 per share, with a possible range of $180.00 to $325.00. If you are interested in AMGN stock, you should also look at its competitors.
27.48% Upside
Amgen Inc Fair Value Forecast for 2023 - 2025 - 2030
Amgen Inc's Price has increased by 15.38% In the last two years, going from $201.70 to $232.73. In the next year, analysts expect Fair Value to reach $261.99 – an increase of 12.57%. For the next eight years, the forecast is for Fair Value to grow by 41.11%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ABBV Stock Forecast | AbbVie | Outperform |
10
|
$136.87 | Buy/Sell | $162.24 | 20.55% |
| GILD Stock Forecast | Gilead Sciences Inc | Outperform |
11
|
$77.89 | Buy/Sell | $87.30 | 12.98% |
| BIIB Stock Forecast | Biogen Inc | Outperform |
11
|
$300.20 | Buy/Sell | $322.44 | 8.26% |
| NasdaqGS:ALXN Stock Forecast | Alexion Pharmaceuticals | - |
15
|
$182.50 | Buy/Sell | $177.38 | 29.40% |
| BMRN Stock Forecast | BioMarin Pharmaceutical | Outperform |
10
|
$93.36 | Buy/Sell | $115.45 | 28.53% |
Amgen Inc Revenue Forecast for 2023 - 2025 - 2030
Amgen Inc's Revenue has increased by 12.67% In the last three years, going from $23.36B to $26.32B. In the next year, analysts expect Revenue to reach $27.32B – an increase of 3.78%. For the next eight years, the forecast is for Revenue to grow by 6.58%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| INCY Stock Forecast | Incyte | Outperform |
9
|
$62.54 | Buy/Sell | $88.18 | 37.51% |
| ARNA Stock Forecast | Arena Pharmaceuticals | - |
6
|
$99.99 | Buy/Sell | $95.80 | 11.05% |
| EXEL Stock Forecast | Exelixis | Outperform |
16
|
$19.19 | Buy/Sell | $24.94 | 30.28% |
.jpg)
Amgen Inc Dividend per Share Forecast for 2023 - 2025 - 2030
In the last three years, Amgen Inc's Dividend per Share has grown, increasing from $5.80 to $8.52 – a growth of 46.90%. In the following year, 11 experts forecast Amgen Inc's Dividend per Share will decrease by 2.82%, to $8.28. Over the next eight years, experts anticipate that Amgen Inc's Dividend per Share will grow at a rate of 48.36%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ARWR Stock Forecast | Arrowhead Pharmaceuticals | Outperform |
7
|
$36.05 | Buy/Sell | $73.38 | 108.04% |
| CCXI Stock Forecast | ChemoCentryx | Outperform |
8
|
$51.99 | Buy/Sell | $34.75 | 24.06% |
| DRNA Stock Forecast | Dicerna Pharmaceuticals | - |
7
|
$38.22 | Buy/Sell | $39.67 | 10.83% |
Amgen Inc Free Cash Flow Forecast for 2023 - 2025 - 2030
In the last three years, Amgen Inc's Free Cash Flow has grown from $8.53B to $8681.00T – a 101746259.49% increase. In the next year, 5 analysts estimate that Amgen Inc's Free Cash Flow will decrease by 100.00%, reaching $10.40B. According to professional forecasts, in 2030, Amgen Inc's Free Cash Flow will decrease by 100.00%, reaching $12.27B.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| FOLD Stock Forecast | Amicus Therapeutics | Outperform |
7
|
$12.17 | Buy/Sell | $14.60 | 23.25% |
| BCRX Stock Forecast | BioCryst Pharmaceuticals | Outperform |
7
|
$8.35 | Buy/Sell | $17.08 | 55.69% |
| ACAD Stock Forecast | ACADIA Pharmaceuticals | Outperform |
6
|
$24.61 | Buy/Sell | $29.50 | -18.73% |
Amgen Inc Net Income Forecast for 2023 - 2025 - 2030
In the last three years, Amgen Inc's Net Income has seen a drop from $7.84B to $6.55B – a 16.45% decrease. For the next year, analysts are expecting Net Income to reach $10.25B – an increase of 56.44%. Over the next eight years, experts predict that Net Income will grow by 50.36%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BPMC Stock Forecast | Blueprint Medicines | Outperform |
6
|
$44.99 | Buy/Sell | $119.23 | 74.48% |
| SAGE Stock Forecast | Sage Therapeutics | Outperform |
6
|
$49.82 | Buy/Sell | $101.45 | 8.39% |
| IOVA Stock Forecast | Iovance Biotherapeutics | Outperform |
4
|
$8.80 | Buy/Sell | $34.92 | 206.82% |
Amgen Inc EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, Amgen Inc's EBITDA has fallen from $11.76B to $8.75B – a 25.55% decrease. For next year, analysts predict EBITDA of $16.28B, which would mean an increase of 85.98%. Over the next eight years, experts predict that Amgen Inc's EBITDA will grow at a rate of 49.55%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| FATE Stock Forecast | Fate Therapeutics | Outperform |
7
|
$5.25 | Buy/Sell | $109.67 | 1461.90% |
| DVAX Stock Forecast | Dynavax Technologies | Buy |
11
|
$11.66 | Buy/Sell | $22.67 | 127.27% |
| XNCR Stock Forecast | Xencor | Buy |
6
|
$27.69 | Buy/Sell | $55.00 | 78.76% |
Amgen Inc EBIT Forecast for 2023 - 2025 - 2030
In the last two years, Amgen Inc's EBIT has decreased from $9.72B to $9.34B – a 3.94% drop. For next year, analysts predict EBIT of $13.01B, which would mean an increase of 39.31%. Over the next eight years, experts predict that Amgen Inc's EBIT will grow at a rate of 35.96%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CLDX Stock Forecast | Celldex Therapeutics | Buy |
11
|
$33.19 | Buy/Sell | $64.83 | 104.88% |
| TVTX Stock Forecast | Travere Therapeutics | Buy |
8
|
$19.05 | Buy/Sell | $41.00 | 120.47% |
| AGIO Stock Forecast | Agios Pharmaceuticals | Outperform |
9
|
$26.05 | Buy/Sell | $53.75 | 49.71% |
Amgen Inc EPS Price Prediction Forecast for 2023 - 2025 - 2030
Amgen Inc's EPS has increased by 15.38% In the last two years, going from $14.82 to $17.10. In the next year, analysts expect EPS to reach $19.25 – an increase of 12.57%. For the next eight years, the forecast is for EPS to grow by 41.11%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ENTA Stock Forecast | Enanta Pharmaceuticals | Outperform |
10
|
$25.93 | Buy/Sell | $90.20 | 158.39% |
| VCEL Stock Forecast | Vericel | Buy |
8
|
$32.93 | Buy/Sell | $44.60 | 51.84% |
| RVNC Stock Forecast | Revance Therapeutics | Outperform |
6
|
$31.06 | Buy/Sell | $38.55 | -17.90% |
.jpg)